Provided by Tiger Trade Technology Pte. Ltd.

Carisma Therapeutics, Inc.

0.0457
+0.006516.58%
Volume:48.69K
Turnover:2.02K
Market Cap:1.91M
PE:0.24
High:0.0459
Open:0.0459
Low:0.0389
Close:0.0392
52wk High:1.27
52wk Low:0.0307
Shares:41.85M
Float Shares:31.26M
Volume Ratio:0.36
T/O Rate:0.16%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.1920
EPS(LYR):-1.4588
ROE:-362.79%
ROA:33.03%
PB:-2.21
PE(LYR):-0.03

Loading ...

Company Profile

Company Name:
Carisma Therapeutics, Inc.
Exchange:
PINK
Establishment Date:
2016
Employees:
46
Office Location:
3675 Market Street,Suite 401,Philadelphia,Pennsylvania,United States
Zip Code:
19104
Fax:
- -
Introduction:
Carisma Therapeutics, Inc., a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others. It is also developing in vivo CAR-M cell therapies in collaboration with Moderna Therapeutics to address multiple cancer targets; and multiple assets for the potential treatment of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.